MedTrace Logo

BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes

NCT00389402 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2010-06-11

No results posted yet for this study

Summary

The purpose of this study is to assess differences in changes in plasma lipids between patients on saquinavir/ritonavir or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine as a first-line regimen in patients previously naive for antiretroviral therapy. This study is an extension from the SSAR 2004/0002 which randomised patients over the same treatment arms.

Conditions

  • HIV Infections

Interventions

DRUG

saquinavir/ritonavir

DRUG

atazanavir/ritonavir

Sponsors & Collaborators

Principal Investigators

  • Peter Reiss, MD, PhD · Academic Medical Centre, University of Amsterdam, the Netherlands

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Completion
2008-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00389402 on ClinicalTrials.gov